MedicaidPrior AuthMedium impact
Erwinase® (asparaginase Erwinia chrysanthemi) (New)
Humana·LA · Oncology, Hematology, Pediatrics·Medicaid
Effective date
Nov 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established new prior authorization requirements for Erwinase (asparaginase Erwinia chrysanthemi) for acute lymphoblastic leukemia (ALL) patients. The policy requires documented Grade 2-4 hypersensitivity to prior Oncaspar treatment and excludes patients with history of serious pancreatitis, thrombosis, hemorrhage, or disease progression on asparaginase therapy.
Action Required
By November 1, 2025: Billing team must update prior authorization workflow for Erwinase injections for Louisiana Medicaid patients. Ensure providers document ALL diagnosis, Grade 2-4 hypersensitivity to Oncaspar, use as part of multi-agent chemotherapy regimen, and absence of exclusionary conditions (pancreatitis, thrombosis, hemorrhage, disease progression history). Visit www.humana.com/PAL for specific procedure codes requiring authorization. Claims will be denied without proper prior authorization.